2021.04.27 2021.4-Biocentury: I-Mab is pursuing mRNA therapies, eyeing orally delivered antibodies for ‘third wave’ of its immuno-oncology pipeline
2021.04.15 2021.4-Biocentury: Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making
2021.04.14 I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021.04.06 I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
2021.03.30 I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors